A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)
This Study is
No Longer Enrolling
Details
Age
Adult
Eligibility
Diagnosis of SLE made at least 6 months prior to Screening.
Type of Study
Treatment
Locations
Outpatient CTRC
University of Colorado Hospital
Study ID
Protocol Number: 18-2346
More information available at ClinicalTrials.gov: NCT03742037
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers